Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Roots Analysis | PRODUCT CODE: 1162461

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 1162461

Cell and Gene Therapy CRO Market : Distribution by Area of Expertise, Scale of Operation, Therapeutic Area, and Geography : Industry Trends and Global Forecasts, 2022-2035

PUBLISHED:
PAGES: 330 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 5899
PDF (Site License)
USD 7999
PDF (Department License)
USD 10599
PDF (Enterprise License)
USD 17999

Add to Cart

INTRODUCTION

Cell and gene therapy candidates have been demonstrated to have the potential to treat rare and complex diseases, including indications, for which no effective treatment is currently available. In this context, it is important to mention that, in case of cell therapy, human cells are transplanted to repair or replace the damaged cells / tissues, thereby, enabling their treatment through alteration or restoration of certain sets of cells. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells). On the other hand, gene therapy aims to correct the underlying genetic problem to ensure the treatment, as well as prevention of diseases, by replacing, inactivating or introducing genes into cells, either inside or outside of the body. It is worth highlighting that some therapeutic interventions can be considered both cell and gene therapies. The mechanism of action of such therapies usually involves alteration of genes in specific types of cells and then, their insertion into the patient body.

Q1. How is the research and development activity evolving in the cell and gene therapy industry?

At present, cell and gene therapy industry is one of the fastest growing therapeutic segments, already having contributed to some of the most significant disruptions in the biopharmaceutical domain. Till date, 23 cell and gene therapies have been approved by the Food and Drug Administration (FDA) in the US, while more than 1,000 IND applications have been filed for candidates being evaluated in ongoing clinical studies. This further indicates a remarkable scientific progress and therapeutic promise of these breakthrough drug candidates.

Q2. What is the need for contract research organizations (CROs) in the cell and gene therapy CROs domain?

At present, only a few therapeutic developers have the required technical expertise to carry out in-house clinical research. This can be attributed to the high costs associated with acquiring the necessary infrastructure and capabilities to carry out research. Other key concerns shared by contemporary innovators include limited availability of expertise, high rate of attrition of pipeline drugs / therapies and prolonged development timelines. The aforementioned challenges are believed to be the key factors for driving the outsourcing of research operations to the CROs, which claim to be well-aware of the nuances of advanced therapy medicinal products (ATMPs) design and development, as well as cell and gene therapy manufacturing process.

Q3. What are the current market opportunities in the cell and gene therapy CROs market?

Due to the upsurge in the research and development related to genetic engineering, there has been a considerable increase in the development of cell and gene therapies. Consequently, there has been a parallel rise in outsourcing of services as more clinical studies are anticipated to start. Specifically, cell and gene therapy companies have made significant investments to support the development / adoption of advanced tools, technologies and platforms, to generate more robust and evidence based clinical data, which is required for gaining the marketing authorizations across different geographies. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. Further, CROs are believed to play a significant role in the successful approval of these drugs in a highly evolving regulatory environment. Since 2005, over 40 CROs have been established in this domain. It is worth mentioning that cell and gene therapy CROs are bolstering their existing capabilities to offer a wide range of services to their clients.

Q4. What are the recent developments and expected trends in the cell and gene therapy industry?

Presently, more than 3,570 cell and gene therapies are being evaluated across various stages of clinical development for a myriad of disease indications. Given that the demand for cell and gene therapies is indubitably rising, more than 53% mergers and acquisitions have been undertaken by service providers in this market, since 2015. Considering the prevalent trends and projected opportunity associated with the overall cell and gene therapies market, we believe that the cell and gene therapy CROs market is likely to witness consistent grow, till 2035 .

Q5. What are the key challenges faced by cell and gene therapy CROs?

One of the key challenges faced by CROs focused on cell and gene therapies is the lack of understanding of the standard operating procedures (SOPs). In addition, various regulatory guidelines render therapies subject to rigorous quality assessments, thereby, making it difficult for firms with limited finances to undertake research initiatives.

Q6. What are the key value drivers in the cell and gene therapy market?

A significant rise in healthcare expenditure, R&D spending and booming research have emerged as key value drivers in the cell and gene therapy domain.

Q7. How is the revenue generation potential associated with cell and gene therapy CROs likely to evolve in the coming years?

The cell and gene therapy CROs market is likely to witness a substantial growth in the coming years. It is worth mentioning that, presently in terms of area of expertise, the market is likely to be driven by cell therapies, and this trend is unlikely to change in the foreseen future as well. Further, based on scale of operation, majority of the revenue share is likely to be associated with clinical operations. Specifically, in terms of global regions, the cell and gene therapy market in Asia-Pacific is likely to grow at a relatively faster pace (21%), in the long term.

Q8. Who are the key players engaged in the cell and gene therapy CROs market?

The key players engaged in this domain (which have also been capture in this report) include Altasciences, Allucent, Accelera Charles River Laboratories, Creative Biolabs, CMIC, Evotec, ICON, IQVIA, Labcorp, Medpace, PPD, Precision For Medicine, QPS and Syneos Health.

SCOPE OF THE REPORT

The "Cell and Gene Therapy CROs Market (3rd Edition), 2022-2035: Distribution by Area of Expertise (Cell Therapy and Gene Therapy), Scale of Operation (Clinical, Preclinical and Discovery), Therapeutic Area (Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Infectious Diseases, Metabolic Disorders, Autoimmune Disorders, Blood Disorders, Rare / Genetic Disorders, Ophthalmological Disorders, and Other disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa)" report features an extensive study of the current market landscape and future potential of the cell and gene therapy CROs market, over the next decade.

The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of the cell and gene therapy CROs, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, area of expertise (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operation (discovery, preclinical, clinical and commercial) and types of services offered, including [A] preclinical services (bioanalytical services, in-vivo studies, pharmacokinetic and ADME services, preclinical safety studies, toxicology studies and other preclinical services), [B] clinical services (clinical research monitoring, clinical trial management/ clinical project management, data management, safety and pharmacovigilance, and other clinical services), [C] regulatory services (GAP analysis, IND preparation, legal representation and technical dossier submission) and [D] general support services (biostatistics, consulting, post-market assessment, re-imbursement and training).
  • A detailed analysis on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies. In addition, it includes information on various factors that drive developers towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.
  • Elaborate profiles of key industry players (very large and large companies) based in North America, Europe and Asia-Pacific that offer contract research services for both cell and gene therapies across both preclinical and clinical scales of operation. Each profile features a brief overview of the company, along with details related to its cell and gene therapies-related service portfolio, recent developments, and an informed future outlook.
  • A benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to gain a competitive edge in the industry.
  • An analysis of the recent collaborations within the cell and gene therapy contract research industry, based on several relevant parameters, such as year of partnership, type of partnership, area of expertise, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2022, based on several parameters, such as year, type of agreement, area of expertise, geographical location of the companies and key value drivers.
  • A detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • A list of over 310 cell therapy developers that are anticipated to partner with cell therapy CROs. These players have been shortlisted based on several relevant parameters, such as developer strength (based on company's size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), and availability of other cell therapy capabilities.
  • An in-depth analysis of nearly 235 gene therapy developers that are anticipated to partner with gene therapy CROs and have been shortlisted on the basis of several relevant parameters, such as developer strength (based on company's size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various cell and gene therapies, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), therapeutic area and key geographical regions.
  • A detailed analysis of the total cost of ownership for large / very large cell and gene therapy contract research organizations. It features an informed estimate of direct and indirect expenses taking into consideration various relevant parameters, over a span of 20 years.
  • A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.

One of the key objectives of this report was to evaluate the current opportunity and the future growth potential of the cell and gene therapy CROs market over the coming years. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across important parameters, such as [A] area of expertise (cell therapy and gene therapy), [B] scale of operation (clinical, preclinical and discovery), [C] therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, infectious diseases, metabolic disorders, autoimmune disorders, blood disorders, rare / genetic disorders, ophthalmological disorders, and other disorders), and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of cell and gene therapy CROs market and its likely evolution in the mid-long term.

Chapter 3 provides a general introduction to CROs, featuring insights on the historical evolution of such organizations, legacy and contemporary trends in outsourcing activity. It provides a brief introduction to the concept of CROs, featuring a discussion on the historical evolution of contract research services market in this domain. Additionally, the chapter includes details on the various types of services offered by different types of CROs. Further, the chapter highlights the advantages and risks associated in partnering with contract service providers, and their role in the development of ATMPs.

Chapter 4 provides a detailed discussion on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies. In addition, it includes information on various factors that drive sponsors towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.

Chapter 5 provides a detailed review of the overall landscape of the cell and gene therapy services market, highlighting the contributions of CROs, along with the information on their year of establishment, company size, location of headquarters, area of expertise (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operation (discovery, preclinical, clinical and commercial) and types of services offered, including [A] preclinical services (bioanalytical services, in-vivo studies, pharmacokinetic and ADME services, preclinical safety studies, toxicology studies and other preclinical services), [B] clinical services (clinical research monitoring, clinical trial management/ clinical project management, data management, safety and pharmacovigilance, and other clinical services), [C] regulatory services (GAP analysis, IND preparation, legal representation and technical dossier submission) and [D] general support services (biostatistics, consulting, post-market assessment, re-imbursement and training).

Chapter 6 features an elaborate profiles of key industry players (very large and large companies) based in North America, Europe and Asia-Pacific that offer contract research services for both cell and gene therapies across both preclinical and clinical scales of operation. Each profile features a brief overview of the company, details related to its cell and gene therapies-related service portfolio, recent developments, and an informed future outlook.

Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.

Chapter 8 features an analysis of the recent collaborations within the cell and gene therapy contract research industry, based on several relevant parameters, such as year of partnership, type of partnership, area of expertise, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have taken place in this domain, during the period 2015-2022.

Chapter 9 presents a detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2022. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year, type of agreement, area of expertise, geographical location of the companies and key value drivers.

Chapter 10 provides a detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 11 features an in-depth analysis of over 310 cell therapy developers that are anticipated to partner with cell therapy CROs. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company's size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), and availability of other cell therapy capabilities.

Chapter 12 features an in-depth analysis of nearly 235 gene therapy developers that are anticipated to partner with gene therapy CROs and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company's size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.

Chapter 13 features an in-depth analysis of completed, ongoing, and planned clinical studies of various cell and gene therapies, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), therapeutic area and key geographical regions.

Chapter 14 presents a detailed analysis of the total cost of ownership for large / very large cell and gene therapy contract research organizations. It features an informed estimate of direct and indirect expenses taking into consideration various relevant parameters, over a span of 20 years.

Chapter 15 features a comprehensive market forecast analysis, highlighting the likely growth of cell and gene therapy CROs market, for the time period 2022-2035. In order to provide details on the future outlook, our projections have been segmented on the basis of [A] area of expertise (cell therapy and gene therapy) [B] scale of operation (clinical, preclinical and discovery), [C] therapeutic area (Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Infectious Diseases, Metabolic Disorders, Autoimmune Disorders, Blood Disorders, Rare / Genetic Disorders, Ophthalmological Disorders, and Other disorders), and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).

Chapter 16 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.

Chapter 17 is a summary of the entire report. The chapter provides the key takeaways from the report, and presents our independent opinion of the cell and gene therapy CROs market, based on the research and analysis described in the previously mentioned chapters.

Chapter 18 is a collection of interview transcripts of the discussions that were held key stakeholders in the industry.

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which contains a list of companies and organizations mentioned in this report.

Product Code: RA100381

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

  • 2.1. Chapter Overview

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Contract Research Organizations (CROs)
    • 3.2.1. Evolution of CROs
    • 3.2.2. Modern CROs and Prevalent Outsourcing Trends
  • 3.3. Type of Services Offered by CROs
  • 3.4. Classification of CROs
  • 3.5. Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs)
  • 3.6. Advantages of Outsourcing Operations to CROs
  • 3.7. Risks Associated with Outsourcing to CROs
  • 3.8. Future Perspectives

4. GUIDE TO OUTSOURCING

  • 4.1. Chapter Overview
  • 4.2. Outsourcing Cell and Gene Therapy Research
  • 4.3. Guiding Models of Outsourcing
    • 4.3.1. Transactional Outsourcing Model
    • 4.3.2. Performance / Outcome-based Business Model
    • 4.3.3. Staff Augmentation Model
    • 4.3.4. Phase-Dependent Outsourcing Models
  • 4.4. Selecting an Appropriate Outsourcing Model
    • 4.4.1. Hybrid Approach
  • 4.5. Selecting a CRO Partner
    • 4.5.1 Key Considerations while Outsourcing Cell and Gene Therapy-related Operations
  • 4.6. Role of CROs in Drug Development
    • 4.6.1. Discovery and Preclinical Research
    • 4.6.2. Early Clinical Research
    • 4.6.3. Clinical Research and Laboratory Services
  • 4.7. Concluding Remarks

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Cell and Gene Therapy CROs: Overall Market Landscape
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Location of Headquarters
    • 5.2.4. Analysis by Scale of Operation
    • 5.3.5. Analysis by Area of Expertise
    • 5.3.6. Analysis by Number of Preclinical Services
    • 5.3.7. Analysis by Type of Preclinical Service(s) Offered
    • 5.3.8. Analysis by Number of Clinical Services
    • 5.3.9. Analysis by Type of Clinical Service(s) Offered
    • 5.3.10. Analysis by Type of Regulatory Service(s) Offered
    • 5.3.11. Analysis by Type of General Support Service(s) Offered

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Players based in North America
    • 6.2.1. Altasciences
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Service Portfolio
      • 6.2.1.3. Recent Developments and Future Outlook
    • 6.2.2. Allucent (Formerly Known as CATO SMS)
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Service Portfolio
      • 6.2.2.3. Recent Developments and Future Outlook
    • 6.2.3. Charles River Laboratories
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Information
      • 6.2.3.3. Service Portfolio
      • 6.2.3.4. Recent Developments and Future Outlook
    • 6.2.4. Creative Biolabs
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Service Portfolio
      • 6.2.4.3. Recent Developments and Future Outlook
    • 6.2.5. IQVIA
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Information
      • 6.2.5.3. Service Portfolio
      • 6.2.5.4. Recent Developments and Future Outlook
    • 6.2.6. Medpace
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Information
      • 6.2.6.3. Service Portfolio
      • 6.2.6.4. Recent Developments and Future Outlook
    • 6.2.7. PPD
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Information
      • 6.2.7.3. Service Portfolio
      • 6.2.7.4. Recent Developments and Future Outlook
    • 6.2.8. Precision for Medicine
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Service Portfolio
      • 6.2.8.3. Recent Developments and Future Outlook
    • 6.2.9. QPS
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Service Portfolio
      • 6.2.9.3. Recent Developments and Future Outlook
  • 6.3. Players based in Europe
    • 6.3.1. Accelera
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Service Portfolio
      • 6.3.1.3. Recent Developments and Future Outlook
    • 6.3.2. Evotec
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Financial Information
      • 6.3.2.3. Service Portfolio
      • 6.3.2.4. Recent Developments and Future Outlook
    • 6.3.3. ICON
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Service Portfolio
      • 6.3.3.3. Recent Developments and Future Outlook
    • 6.3.4. Syneos Health
      • 6.3.4.1. Company Overview
      • 6.3.4.2. Financial Information
      • 6.3.4.3. Service Portfolio
      • 6.3.4.4. Recent Developments and Future Outlook
  • 6.4. Players based in Asia-Pacific
      • 6.4.1.1. CMIC Group
      • 6.4.1.2. Company Overview
      • 6.4.1.3. Financial Information
      • 6.4.1.4. Service Portfolio
      • 6.4.1.5. Recent Developments and Future Outlook
    • 6.4.2. Labcorp
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Financial Information
      • 6.4.2.3. Service Portfolio
      • 6.4.2.4. Recent Developments and Future Outlook

7. COMPETITIVE BENCHMARKING

  • 7.1. Chapter Overview
  • 7.2. Assumptions and Key Methodology
  • 7.3. Competitive Benchmarking by Region
    • 7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
    • 7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
    • 7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
    • 7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
    • 7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
    • 7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
    • 7.3.7. Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific and RoW (Peer Group VII)
  • 7.4. Concluding Remarks

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Cell and Gene Therapy CROs: Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year and Type of Partnership
    • 8.3.4. Analysis by Type of Partnership and Company Size
    • 8.3.5. Analysis by Area of Expertise
    • 8.3.6. Analysis by Year of Partnership and Area of Expertise
    • 8.3.7. Analysis by Type of Partnership and Area of Expertise
    • 8.3.8. Most Active Players: Analysis by Number of Partnerships
    • 8.3.9. Analysis by Region
      • 8.3.9.1. Intracontinental and Intercontinental Deals
      • 8.3.9.2. Local and International Deals

9. MERGERS AND ACQUISITIONS

  • 9.1. Chapter Overview
  • 9.2. Merger and Acquisition Models
  • 9.3. Cell and Gene Therapy CROs: Mergers and Acquisitions
    • 9.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
    • 9.3.2. Analysis by Type of Agreement
    • 9.3.3. Analysis by Region
      • 9.3.3.1. Mergers and Acquisitions: Continent-wise Distribution
      • 9.3.3.2. Mergers and Acquisitions: Country-wise Distribution
    • 9.3.4. Most Active Acquirers: Analysis by Number of Acquisitions
    • 9.3.5. Analysis by Key Value Drivers
    • 9.3.6. Analysis by Year of Acquisition and Key Value Drivers
    • 9.3.7. Key Acquisitions: Deal Multiples

10. KEY ACQUISITION TARGETS

  • 10.1. Chapter Overview
  • 10.2. Scoring Criteria and Key Assumptions
  • 10.3. Scope and Methodology
  • 10.4. Potential Strategic Acquisition Targets Amongst Small Players
  • 10.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players

11. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs

  • 11.1. Chapter Overview
  • 11.2. Scoring Criteria and Key Assumptions
  • 11.3. Scope and Methodology
  • 11.4. Key Potential Strategic Partners for Cell Therapy CROs
    • 11.4.1. Likely Partner Opportunities for Dendritic Cell Therapy CROs
    • 11.4.2. Likely Partner Opportunities for NK Cell Therapy CROs
    • 11.4.3. Likely Partner Opportunities for Stem Cell Therapy CROs
    • 11.4.4. Likely Partner Opportunities for T-Cell Therapy CROs

12. LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs

  • 12.1. Chapter Overview
  • 12.2. Scoring Criteria and Key Assumptions
  • 12.3. Scope and Methodology
  • 12.4. Key Potential Strategic Partners for Gene Therapy CROs
    • 12.4.1. Likely Partner Opportunities in North America
    • 12.4.2. Likely Partner Opportunities in Europe
    • 12.4.3. Likely Partner Opportunities in Asia-Pacific and RoW

13. CLINICAL TRIAL ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Cell Therapies: Analysis by Number of Clinical Trials
    • 13.3.1. Analysis by Trial Registration Year
    • 13.3.2. Analysis by Trial Status
    • 13.3.3. Analysis by Trial Phase
    • 13.3.4. Analysis by Therapeutic Area
    • 13.3.5. Analysis by Type of Sponsor
    • 13.3.6. Analysis by Geography
    • 13.3.7. Analysis by Trial Registration Year and Geography
    • 13.3.8. Analysis by Trial Status and Geography
    • 13.3.9. Analysis by Trial Phase and Geography
  • 13.4. Cell Therapies: Analysis by Enrolled Patient Population
    • 13.4.1. Analysis by Trial Registration Year
    • 13.4.2. Analysis by Trial Status
    • 13.4.3. Analysis by Trial Phase
    • 13.4.4. Analysis by Location of Trial Site
    • 13.4.5. Analysis by Trial Status and Location of Trial Site
    • 13.4.6. Analysis by Trial Status, Trial Phase and Location of Trial Site
  • 13.5. Gene Therapies: Analysis by Number of Clinical Trials
    • 13.5.1. Analysis by Trial Registration Year
    • 13.5.2. Analysis by Trial Status
    • 13.5.3. Analysis by Trial Phase
    • 13.5.4. Analysis by Therapeutic Area
    • 13.5.5. Analysis by Type of Sponsor
    • 13.5.6. Analysis by Location of Trial Site
    • 13.5.7. Analysis by Geography
    • 13.5.8. Analysis by Trial Registration Year and Geography
    • 13.5.9. Analysis by Trial Status and Geography
    • 13.5.10. Analysis by Trial Status, Trial Phase and Geography
    • 13.5.11. Analysis by Therapeutic Area and Geography
  • 13.6. Gene Therapies: Analysis by Enrolled Patient Population
    • 13.6.1. Analysis by Trial Registration Year
    • 13.6.2. Analysis by Trial Status
    • 13.6.3. Analysis by Trial Phase
    • 13.6.4. Analysis by Therapeutic Area
    • 13.6.5. Analysis by Location of Trial Site
    • 13.6.6. Analysis by Trial Status and Location of Trial Site
    • 13.6.7. Analysis by Trial Status, Trial Phase and Location of Trial Site
    • 13.6.8. Analysis by Therapeutic Area and Location of Trial Site

14. TOTAL COST OF OWNERSHIP FOR CELL AND GENE THERAPY CONTRACT RESEARCH ORGANIZATIONS

  • 14.1 Chapter Overview
  • 14.2. Key Parameters
  • 14.3. Assumptions and Methodology
  • 14.4. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2022-2042
    • 14.4.1. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX and OPEX, 2023-2042
    • 14.4.2. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX, 2023-2042
    • 14.4.3. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by OPEX, 2023-2042

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Global Cell and Gene Therapy CROs Market, 2022-2035
    • 15.3.1. Cell and Gene Therapy CROs Market: Analysis by Area of Expertise
      • 15.3.1.1. Cell Therapy CROs Market, 2022-2035
      • 15.3.1.2. Gene Therapy CROs Market, 2022-2035
    • 15.3.2. Cell and Gene Therapy CROs Market: Analysis by Scale of Operation
      • 15.3.2.1. Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035
      • 15.3.2.2. Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035
      • 15.3.2.3. Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035
    • 15.3.3. Cell and Gene Therapy CROs Market: Analysis by Therapeutic Area, 2022-2035
      • 15.3.3.1. Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035
      • 15.3.3.2. Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035
      • 15.3.3.3. Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035
      • 15.3.3.4. Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035
      • 15.3.3.5. Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035
      • 15.3.3.6. Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035
      • 15.3.3.7. Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035
      • 15.3.3.8. Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035
      • 15.3.3.9. Cell and Gene Therapy CROs Market for Ophthalmological Disorders, 2022-2035
      • 15.3.3.10. Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035
    • 15.3.4. Cell and Gene Therapy CROs Market: Analysis by Geography, 2022-2035
      • 15.3.4.1. Cell and Gene Therapy CROs Market in North America, 2022-2035
      • 15.3.4.2. Cell and Gene Therapy CROs Market in Europe, 2022-2035
      • 15.3.4.3. Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035
      • 15.3.4.4. Cell and Gene Therapy CROs Market in Latin America, 2022-2035
      • 15.3.4.5. Cell and Gene Therapy CROs Market in MENA, 2022-2035

16. SWOT ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Strengths
  • 16.3. Weaknesses
  • 16.4. Opportunities
  • 16.5. Threats
  • 16.6. Comparison of SWOT Factors

17. CONCLUSION

  • 17.1. Chapter Overview

18. INTERVIEW AND SURVEY TRANSCRIPTS

  • 18.1. Chapter Overview
  • 18.2. CATO SMS
    • 18.2.1. Company Snapshot
    • 18.2.2. Survey Transcript: Jessica Bliven, Director, Marketing and Sales
  • 18.3. Changhai Hospital, Second Military Medical University
    • 18.3.1. University Snapshot
    • 18.3.2. Survey Transcript: Xian-Bao Zhan, Professor of Medicine, Director, Department of Oncology
  • 18.4. University of Colorado
    • 18.4.1. University Snapshot
    • 18.4.2. Survey Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100381

LIST OF TABLES

  • Table 3.1 List of Approved ATMP Products
  • Table 4.1 Attributes of Transactional Outsourcing-based Business Model
  • Table 5.1 List of Cell and Gene Therapy CROs
  • Table 5.2 Cell and Gene Therapy CROs: Information on Type of Preclinical Service(s) Offered
  • Table 5.3 Cell and Gene Therapy CROs: Information on Type of Clinical Service(s) Offered
  • Table 5.4 Cell and Gene Therapy CROs: Information on Type of Regulatory Service(s) Offered
  • Table 5.5 Cell and Gene Therapy CROs: Information on Type of General Service(s) Offered
  • Table 6.1 Altasciences: Company Overview
  • Table 6.2 Altasciences: Recent Developments and Future Outlook
  • Table 6.3 Allucent (Formerly known as CATO SMS): Company Overview
  • Table 6.4 Allucent (Formally Known as CATO SMS): Recent Developments and Future Outlook
  • Table 6.5 Charles River Laboratories: Company Overview
  • Table 6.6 Charles River Laboratories: Recent Developments and Future Outlook
  • Table 6.7 Creative Biolabs: Company Overview
  • Table 6.8 IQVIA: Company Overview
  • Table 6.9 Medpace: Company Overview
  • Table 6.10 PPD: Company Overview
  • Table 6.11 PPD: Recent Developments and Future Outlook
  • Table 6.12 Precision for Medicine: Company Overview
  • Table 6.13 Precision for Medicine: Recent Developments and Future Outlook
  • Table 6.14 QPS: Company Overview
  • Table 6.15 Accelera: Company Overview
  • Table 6.16 Evotec: Company Overview
  • Table 6.17 ICON: Company Overview
  • Table 6.18 ICON: Recent Developments and Future Outlook
  • Table 6.19 Syneos Health: Company Overview
  • Table 6.20 Syneos Health: Recent Developments and Future Outlook
  • Table 6.21 CMIC Group: Company Overview
  • Table 6.22 CMIC Group: Recent Developments and Future Outlook
  • Table 6.23 Labcorp: Company Overview
  • Table 6.24 Labcorp: Recent Developments and Future Outlook
  • Table 7.1 Benchmark Analysis: Peer Groups
  • Table 8.1 Cell and Gene Therapy CROs: List of Partnerships and Collaborations, 2015-2022
  • Table 9.1 Cell and Gene Therapy CROs: List of Mergers and Acquisitions, 2015-2022
  • Table 9.2 Cell and Gene Therapy CROs Mergers and Acquisitions: Information on Key Value Drivers and Area of Expertise, 2015-2022
  • Table 9.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2022
  • Table 10.1 Potential Strategic Acquisition Targets Amongst Small Players
  • Table 10.2 Potential Strategic Acquisition Targets Amongst Mid-sized Players
  • Table 11.1 Likely Partners for Dendritic Cell Therapy CROs
  • Table 11.2 Likely Partners for NK Cell Therapy CROs
  • Table 11.3 Likely Partners for Stem Cell Therapy CROs
  • Table 11.4 Likely Partners for T-Cell Therapy CROs
  • Table 12.1 Likely Partner Opportunities in North America
  • Table 12.2 Likely Partner Opportunities in Europe
  • Table 12.3 Likely Partner Opportunities in Asia-Pacific and RoW
  • Table 13.1 Clinical Trial Analysis: Emerging Molecules
  • Table 13.2 Clinical Trial Analysis: Most Important Trials
  • Table 19.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
  • Table 19.2 Cell and Gene Therapy CROs: Distribution by Company Size
  • Table 19.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region-wise)
  • Table 19.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country-wise)
  • Table 19.5 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Table 19.6 Cell and Gene Therapy CROs: Distribution by Scale of Operation
  • Table 19.7 Cell and Gene Therapy CROs: Distribution by Area of Expertise
  • Table 19.8 Cell and Gene Therapy CROs: Distribution by Scale of Operation and Area of Expertise
  • Table 19.9 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
  • Table 19.10 Cell and Gene Therapy CROs: Distribution by Number of Preclinical Services
  • Table 19.11 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Service(s) Offered
  • Table 19.12 Cell and Gene Therapy CROs: Distribution by Number of Clinical Services
  • Table 19.13 Cell and Gene Therapy CROs: Distribution by Type of Clinical Service(s) Offered
  • Table 19.14 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Service(s) Offered
  • Table 19.15 Cell and Gene Therapy CROs: Distribution by Type of General Service(s) Offered
  • Table 19.16 Charles River Laboratories: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
  • Table 19.17 IQVIA: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
  • Table 19.18 Medpace: Annual Revenues, FY 2017-Q1 2022 (USD Million)
  • Table 19.19 PPD: Annual Revenues, FY 2017-9M 2021 (USD Billion)
  • Table 19.20 Evotec: Annual Revenues, FY 2017-Q1 2022 (EUR Million)
  • Table 19.21 Syneos Health: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
  • Table 19.22 CMIC Group: Annual Revenues, 2017-H1 2022 (JPY Billion)
  • Table 19.23 Labcorp: Annual Revenues, FY 2017- Q1 2022 (USD Billion)
  • Table 19.24 Benchmark Analysis: Distribution by Location of Headquarters and Company Size
  • Table 19.25 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
  • Table 19.26 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 19.27 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
  • Table 19.28 Partnerships and Collaborations: Distribution by Area of Expertise
  • Table 19.29 Partnerships and Collaborations: Distribution by Year of Partnership and Area of Expertise
  • Table 19.30 Most Active Players: Distribution by Number of Partnerships
  • Table 19.31 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
  • Table 19.32 Partnerships and Collaborations: Local and International Deals
  • Table 19.33 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2022
  • Table 19.34 Mergers and Acquisitions: Distribution by Type of Agreement
  • Table 19.35 Mergers and Acquisitions: Distribution by Region (Continent-wise)
  • Table 19.36 Mergers and Acquisitions: Distribution by Region (Country-wise)
  • Table 19.37 Most Active Acquirers: Distribution by Number of Acquisitions
  • Table 19.38 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Table 19.39 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Table 19.40 Mergers and Acquisitions: Deal Multiples Based on Revenues
  • Table 19.41 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
  • Table 19.42 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
  • Table 19.43 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
  • Table 19.44 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area
  • Table 19.45 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
  • Table 19.46 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Number of Registered Trials
  • Table 19.47 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Registration Year
  • Table 19.48 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Status
  • Table 19.49 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Phase
  • Table 19.50 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
  • Table 19.51 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status
  • Table 19.52 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
  • Table 19.53 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population
  • Table 19.54 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
  • Table 19.55 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Phase
  • Table 19.56 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
  • Table 19.57 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
  • Table 19.58 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
  • Table 19.59 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
  • Figure 19.60 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
  • Figure 19.61 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
  • Table 19.62 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Number of Registered Trials
  • Table 19.63 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Registration Year
  • Table 19.64 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status
  • Table 19.65 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status and Trial Phase
  • Table 19.66 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Therapeutic Area
  • Table 19.67 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
  • Table 19.68 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status
  • Table 19.69 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
  • Table 19.70 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Therapeutic Area
  • Table 19.71 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population
  • Table 19.72 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
  • Table 19.73 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status and Trial Phase
  • Table 19.74 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
  • Table 19.75 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2022-2042 (USD Million)
  • Table 19.76 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
  • Table 19.77 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023: Distribution by CAPEX (USD Million)
  • Table 19.78 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023-2042: Distribution by OPEX (USD Million)
  • Table 19.79 Global Cell and Gene Therapy CROs Market 2022-2035 (USD Million)
  • Table 19.80 Cell and Gene Therapy CROs Market: Distribution by Area of Expertise
  • Table 19.81 Cell Therapy CROs Market, 2022-2035 (USD Million)
  • Table 19.82 Gene Therapy CROs Market, 2022-2035 (USD Million)
  • Table 19.83 Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
  • Table 19.84 Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035 (USD Million)
  • Table 19.85 Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035 (USD Million)
  • Table 19.86 Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035 (USD Million)
  • Table 19.87 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
  • Table 19.88 Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035 (USD Million)
  • Table 19.89 Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035 (USD Million)
  • Table 19.90 Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035 (USD Million)
  • Table 19.91 Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035 (USD Million)
  • Table 19.92 Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035 (USD Million)
  • Table 19.93 Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035 (USD Million)
  • Table 19.94 Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035 (USD Million)
  • Table 19.95 Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035 (USD Million)
  • Table 19.96 Cell and Gene Therapy CROs Market for Ophthalmological Disorders, 2022-2035 (USD Million)
  • Table 19.97 Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035
  • Table 19.98 Cell and Gene Therapy CROs Market: Distribution by Geography, 2022 and 2035 (USD Million)
  • Table 19.99 Cell and Gene Therapy CROs Market in North America, 2022-2035 (USD Million)
  • Table 19.100 Cell and Gene Therapy CROs Market in Europe, 2022-2035 (USD Million)
  • Table 19.101 Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035 (USD Million)
  • Table 19.102 Cell and Gene Therapy CROs Market in Latin America, 2022-2035 (USD Million)
  • Table 19.103 Cell and Gene Therapy CROs Market in MENA, 2022-2035 (USD Million)

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Partnerships and Collaborations
  • Figure 2.3 Executive Summary: Mergers and Acquisitions
  • Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Stages of the Drug Development Process
  • Figure 3.2 Services Offered by CROs
  • Figure 3.3 Advantages of Outsourcing Operations to CROs
  • Figure 3.4 Risks Associated with Outsourcing Operations to CROs
  • Figure 3.5 Classification of ATMPs
  • Figure 3.6 Types of Cells Incorporated in Cell Therapy Medicinal Products (CTMPs)
  • Figure 4.1 Guiding Models of Outsourcing
  • Figure 4.2 Key Characteristics of Transactional Outsourcing Model
  • Figure 4.3 Key Characteristics of Performance / Outcome-based Business Model
  • Figure 4.4 Key Considerations while Selecting a CRO Partner
  • Figure 4.5 Role of CROs across Different Phases of Drug Development
  • Figure 5.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
  • Figure 5.2 Cell and Gene Therapy CROs: Distribution by Company Size
  • Figure 5.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region-wise)
  • Figure 5.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country-wise)
  • Figure 5.5 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size, and Location of Headquarters
  • Figure 5.6 Cell and Gene Therapy CROs: Distribution by Scale of Operation
  • Figure 5.7 Cell and Gene Therapy CROs: Distribution by Area of Expertise
  • Figure 5.8 Cell and Gene Therapy CROs: Distribution by Scale of Operation and Area of Expertise
  • Figure 5.9 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
  • Figure 5.10 Cell and Gene Therapy CROs: Distribution by Number of Preclinical Services
  • Figure 5.11 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Service(s) Offered
  • Figure 5.12 Cell and Gene Therapy CROs: Distribution by Number of Clinical Services
  • Figure 5.13 Cell and Gene Therapy CROs: Distribution by Type of Clinical Service(s) Offered
  • Figure 5.14 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Service(s) Offered
  • Figure 5.15 Cell and Gene Therapy CROs: Distribution by Type of General Service(s) Offered
  • Figure 6.1 Altasciences: Service Portfolio
  • Figure 6.2 Allucent (Formerly known as CATO SMS): Service Portfolio
  • Figure 6.3 Charles River Laboratories: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
  • Figure 6.4 Charles River Laboratories: Service Portfolio
  • Figure 6.5 Creative Biolabs: Service Portfolio for CAR-T Therapy Development
  • Figure 6.6 Creative Biolabs: Service Portfolio for TCR Therapy Development
  • Figure 6.7 IQVIA: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
  • Figure 6.8 IQVIA: Service Portfolio
  • Figure 6.9 Medpace: Annual Revenues, FY 2017-Q1 2022 (USD Million)
  • Figure 6.10 Medpace: Service Portfolio
  • Figure 6.11 Medpace: Regulatory Affair Capabilities
  • Figure 6.12 PPD: Annual Revenues, FY 2017-9M 2021 (USD Billion)
  • Figure 6.13 PPD: Service Portfolio
  • Figure 6.14 Precision for Medicine: Service Portfolio
  • Figure 6.15 QPS: Service Portfolio
  • Figure 6.16 Accelera: Service Portfolio
  • Figure 6.17 Evotec: Annual Revenues, FY 2017-Q1 2022 (EUR Million)
  • Figure 6.18 Evotec: Service Portfolio
  • Figure 6.19 ICON: Service Portfolio
  • Figure 6.20 Syneos Health: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
  • Figure 6.21 Syneos Health: Service Portfolio
  • Figure 6.22 CMIC Group: Annual Revenues, 2017-H1 2022 (JPY Billion)
  • Figure 6.23 CMIC Group: Service Portfolio
  • Figure 6.24 Labcorp: Annual Revenues, FY 2017- Q1 2022 (USD Billion)
  • Figure 6.25 Labcorp: Service Portfolio
  • Figure 7.1 Benchmark Analysis: Distribution by Location of Headquarters and Company Size
  • Figure 7.2 Competitive Benchmarking: Small Players based in North America (Peer Group I)
  • Figure 7.3 Competitive Benchmarking: Mid-Sized Players based in North America (Peer Group II)
  • Figure 7.4 Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
  • Figure 7.5 Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
  • Figure 7.6 Competitive Benchmarking: Mid-Sized Players based in Europe (Peer Group V)
  • Figure 7.7 Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
  • Figure 7.8 Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific and RoW (Peer Group VII)
  • Figure 7.9 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
  • Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
  • Figure 8.5 Partnerships and Collaborations: Distribution by Area of Expertise
  • Figure 8.6 Partnerships and Collaborations: Distribution by Year of Partnership and Area of Expertise
  • Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Expertise
  • Figure 8.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.9 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
  • Figure 8.10 Partnerships and Collaborations: Local and International Deals
  • Figure 9.1 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2022
  • Figure 9.2 Mergers and Acquisitions: Distribution by Type of Agreement
  • Figure 9.3 Mergers and Acquisitions: Distribution by Region (Continent-wise)
  • Figure 9.4 Mergers and Acquisitions: Distribution by Region (Country-wise)
  • Figure 9.5 Most Active Acquirers: Distribution by Number of Acquisitions
  • Figure 9.6 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Figure 9.7 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Figure 9.8 Mergers and Acquisitions: Distribution by Deal Multiples Based on Revenues
  • Figure 13.1 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
  • Figure 13.2 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
  • Figure 13.3 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
  • Figure 13.4 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area
  • Figure 13.5 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
  • Figure 13.6 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Number of Registered Trials
  • Figure 13.7 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Registration Year
  • Figure 13.8 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Status
  • Figure 13.9 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Phase
  • Figure 13.10 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
  • Figure 13.11 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status
  • Figure 13.12 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 13.13 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population
  • Figure 13.14 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
  • Figure 13.15 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Phase
  • Figure 13.16 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
  • Figure 13.17 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
  • Figure 13.18 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
  • Figure 13.19 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
  • Figure 13.20 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
  • Figure 13.21 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
  • Figure 13.22 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Number of Registered Trials
  • Figure 13.23 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Registration Year
  • Figure 13.24 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status
  • Figure 13.25 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status and Trial Phase
  • Figure 13.26 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Therapeutic Area
  • Figure 13.27 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
  • Figure 13.28 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status
  • Figure 13.29 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 13.30 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Therapeutic Area
  • Figure 13.31 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population
  • Figure 13.32 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
  • Figure 13.33 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status and Trial Phase
  • Figure 13.34 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
  • Figure 14.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
  • Figure 14.2 Total Cost of Ownership: Operational Expenditures (OPEX)
  • Figure 14.3 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2022-2042 (USD Million)
  • Figure 14.4 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
  • Figure 14.5 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023: Distribution by CAPEX (USD Million)
  • Figure 14.6 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023-2042: Distribution by OPEX (USD Million)
  • Figure 15.1 Global Cell and Gene Therapy CROs Market, 2022-2035 (USD Million)
  • Figure 15.2 Cell and Gene Therapy CROs Market: Distribution by Area of Expertise
  • Figure 15.3 Cell Therapy CROs Market, 2022-2035 (USD Million)
  • Figure 15.4 Gene Therapy CROs Market, 2022-2035 (USD Million)
  • Figure 15.5 Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
  • Figure 15.6 Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035 (USD Million)
  • Figure 15.7 Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035 (USD Million)
  • Figure 15.8 Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035 (USD Million)
  • Figure 15.9 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
  • Figure 15.10 Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035 (USD Million)
  • Figure 15.11 Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035 (USD Million)
  • Figure 15.12 Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035 (USD Million)
  • Figure 15.13 Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035 (USD Million)
  • Figure 15.14 Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035 (USD Million)
  • Figure 15.15 Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035 (USD Million)
  • Figure 15.16 Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035 (USD Million)
  • Figure 15.17 Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035 (USD Million)
  • Figure 15.18 Cell and Gene Therapy CROs Market for Ophthalmological Disorders, 2022-2035 (USD Million)
  • Figure 15.19 Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035 (USD Million)
  • Figure 15.20 Cell and Gene Therapy CROs Market: Distribution by Geography, 2022 and 2035
  • Figure 15.21 Cell and Gene Therapy CROs Market in North America, 2022-2035 (USD Million)
  • Figure 15.22 Cell and Gene Therapy CROs Market in Europe, 2022-2035 (USD Million)
  • Figure 15.23 Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035 (USD Million)
  • Figure 15.24 Cell and Gene Therapy CROs Market in Latin America, 2022-2035 (USD Million)
  • Figure 15.25 Cell and Gene Therapy CROs Market in MENA, 2022-2035 (USD Million)
  • Figure 16.1 Cell and Gene Therapy CROs SWOT Analysis: Overview
  • Figure 17.1 Concluding Remarks: Overall Market Landscape
  • Figure 17.2 Concluding Remarks: Partnerships and Collaborations
  • Figure 17.3 Concluding Remarks: Mergers and Acquisitions
  • Figure 17.4 Concluding Remarks: Clinical Trial Analysis
  • Figure 17.5 Concluding Remarks: Market Sizing and Opportunity Analysis
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!